BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 17121486)

  • 1. Psoriatic arthritis update.
    Mease P
    Bull NYU Hosp Jt Dis; 2006; 64(1-2):25-31. PubMed ID: 17121486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psoriatic arthritis assessment tools in clinical trials.
    Mease PJ; Antoni CE; Gladman DD; Taylor WJ
    Ann Rheum Dis; 2005 Mar; 64 Suppl 2(Suppl 2):ii49-54. PubMed ID: 15708937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psoriatic arthritis treatment: biological response modifiers.
    Mease PJ; Antoni CE
    Ann Rheum Dis; 2005 Mar; 64 Suppl 2(Suppl 2):ii78-82. PubMed ID: 15708944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consensus exercise on domains in psoriatic arthritis.
    Gladman DD
    Ann Rheum Dis; 2005 Mar; 64 Suppl 2(Suppl 2):ii113-4. PubMed ID: 15708924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psoriatic arthritis: update on pathophysiology, assessment and management.
    Mease PJ
    Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i77-84. PubMed ID: 21339225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psoriatic arthritis assessment and treatment update.
    Mease PJ
    Curr Opin Rheumatol; 2009 Jul; 21(4):348-55. PubMed ID: 19461518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psoriatic arthritis - update on pathophysiology, assessment, and management.
    Mease PJ
    Bull NYU Hosp Jt Dis; 2010; 68(3):191-8. PubMed ID: 20969551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psoriatic arthritis: prevalence, diagnosis, and review of therapy for the dermatologist.
    Ruderman EM; Tambar S
    Dermatol Clin; 2004 Oct; 22(4):477-86, x. PubMed ID: 15450343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Composite measures in psoriatic arthritis: GRAPPA 2008.
    Gladman DD; Landewé R; McHugh NJ; Fitzgerald O; Thaci D; Coates L; Mease PJ; Qureshi AA; Krueger GG; Ritchlin CT; Kavanaugh AF; Garg A
    J Rheumatol; 2010 Feb; 37(2):453-61. PubMed ID: 20147481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psoriasis and psoriatic arthritis: clinical features and disease mechanisms.
    Myers WA; Gottlieb AB; Mease P
    Clin Dermatol; 2006; 24(5):438-47. PubMed ID: 16966023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of psoriatic arthritis with biological agents.
    Ceponis A; Kavanaugh A
    Semin Cutan Med Surg; 2010 Mar; 29(1):56-62. PubMed ID: 20430309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis.
    Reich K; Krüger K; Mössner R; Augustin M
    Br J Dermatol; 2009 May; 160(5):1040-7. PubMed ID: 19210498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on treatment of psoriatic arthritis.
    Mease P
    Bull NYU Hosp Jt Dis; 2012; 70(3):167-71. PubMed ID: 23259623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New biologics for psoriasis and psoriatic arthritis.
    Rozenblit M; Lebwohl M
    Dermatol Ther; 2009; 22(1):56-60. PubMed ID: 19222517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoeconomic issues in psoriatic arthritis.
    Olivieri I; D'Angelo S; Palazzi C; Padula A; Lubrano E; Mantovani LG
    J Rheumatol Suppl; 2012 Jul; 89():103-5. PubMed ID: 22751607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A; Esposito M; Costanzo A; Chimenti S
    Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of disease activity measures for psoriatic arthritis: what is the best approach?
    Her M; Kavanaugh A
    Expert Rev Clin Immunol; 2014 Sep; 10(9):1241-54. PubMed ID: 25088300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Arthritis psoriatica].
    de Rie MA; van Kuijk AW; Goedkoop AY; Tak PP
    Ned Tijdschr Geneeskd; 2007 Aug; 151(31):1716-22. PubMed ID: 17784693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis.
    Punzi L; Podswiadek M; Sfriso P; Oliviero F; Fiocco U; Todesco S
    Autoimmun Rev; 2007 Sep; 6(8):524-8. PubMed ID: 17854743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
    Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F
    Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.